PROTIVA FEATURED IN $3.6 MILLION U.S. ARMY GRANT TO DEVELOP TREATMENT FOR EBOLA VIRUS

Protiva Biotherapeutics Inc. announced the intent of the U.S. Defense Threat Reduction Agency to award a US$3.6 million grant to a consortium which includes the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and Protiva. The project will use Protiva's Stable Nucleic Acid Lipid Particle (SNALP) technology to develop a therapy for hemorrhagic fever viral infection, including the Ebola and Marburg viruses. Protiva's portion of the grant is approximately US$1.4 million. Market Wire (http://www.marketwire.com/mw/release_html_pressroom?id=F65B254181F3F030&release_id=164627)